Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Hatz

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Eye (London, England)|December 28, 2022
A systematic evaluation of human expert agreement on optical coherence tomography biomarkers using multiple devicesMartin Michl, Martina Neschi, Alexandra Kaider, et al.
Journal of Clinical Medicine|April 12, 2025
Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular DegenerationKatja Hatz, Aude Ambresin, Martin Schmid, et al.
Scientific Reports|November 21, 2020
Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degenerationAndreas Ebneter, Stephan Michels, Christian Pruente, et al.
Acta Ophthalmologica|October 27, 2019
Ganglion cell layer thickening in well-controlled patients with type 1 diabetes: an early sign for diabetic retinopathy?Bianca S Gerendas, Katja Hatz, Alexandra Kaider, et al.
Diabetes Research and Clinical Practice|January 27, 2019
The prevalence of retinopathy in patients with type 1 diabetes treated with education-based intensified insulin therapy and its association with parameters of glucose controlKatja Hatz, Anna Elisabeth Minder, Roger Lehmann, et al.
The British Journal of Ophthalmology|December 23, 2020
Microvascular abnormalities and long-term efficacy after stereotactic radiotherapy under continued intravitreal anti-VEGF treatment for neovascular AMDKatja Hatz, Frank Zimmermann, Emmanouil Lazaridis, et al.
Klinische Monatsblatter Fur Augenheilkunde|April 20, 2026
Prevention of Postoperative Endophthalmitis after Cataract Surgery with an Intraoperative Gentamycin Antibiotic ProphylaxisSarah Fischer, Philipp Anders, Theo Signer, et al.
Ophthalmology and Therapy|January 12, 2023
Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment AspectsJustus G Garweg, Claudine A Blum, René-Pierre Copt, et al.
Eye (London, England)|December 2, 2022
Transforming ophthalmology in the digital century-new care models with added value for patientsLivia Faes, Peter M Maloca, Katja Hatz, et al.
The British Journal of Ophthalmology|October 11, 2015
Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN studyChristian Prünte, Franck Fajnkuchen, Sajjad Mahmood, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Eye (London, England)|December 28, 2022
A systematic evaluation of human expert agreement on optical coherence tomography biomarkers using multiple devicesMartin Michl, Martina Neschi, Alexandra Kaider, et al.
Journal of Clinical Medicine|April 12, 2025
Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular DegenerationKatja Hatz, Aude Ambresin, Martin Schmid, et al.
Scientific Reports|November 21, 2020
Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degenerationAndreas Ebneter, Stephan Michels, Christian Pruente, et al.
Acta Ophthalmologica|October 27, 2019
Ganglion cell layer thickening in well-controlled patients with type 1 diabetes: an early sign for diabetic retinopathy?Bianca S Gerendas, Katja Hatz, Alexandra Kaider, et al.
Diabetes Research and Clinical Practice|January 27, 2019
The prevalence of retinopathy in patients with type 1 diabetes treated with education-based intensified insulin therapy and its association with parameters of glucose controlKatja Hatz, Anna Elisabeth Minder, Roger Lehmann, et al.
The British Journal of Ophthalmology|December 23, 2020
Microvascular abnormalities and long-term efficacy after stereotactic radiotherapy under continued intravitreal anti-VEGF treatment for neovascular AMDKatja Hatz, Frank Zimmermann, Emmanouil Lazaridis, et al.
Klinische Monatsblatter Fur Augenheilkunde|April 20, 2026
Prevention of Postoperative Endophthalmitis after Cataract Surgery with an Intraoperative Gentamycin Antibiotic ProphylaxisSarah Fischer, Philipp Anders, Theo Signer, et al.
Ophthalmology and Therapy|January 12, 2023
Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment AspectsJustus G Garweg, Claudine A Blum, René-Pierre Copt, et al.
Eye (London, England)|December 2, 2022
Transforming ophthalmology in the digital century-new care models with added value for patientsLivia Faes, Peter M Maloca, Katja Hatz, et al.
The British Journal of Ophthalmology|October 11, 2015
Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN studyChristian Prünte, Franck Fajnkuchen, Sajjad Mahmood, et al.
Pageof 5